LDN for Hashimoto’s Disease: What the Evidence Does and Does Not Show

Low Dose Naltrexone, commonly called LDN, is often discussed online as a possible option for Hashimoto’s thyroiditis. Claims can be broad: that LDN lowers thyroid antibodies, calms autoimmune activity, improves fatigue, restores thyroid function, reduces the need for levothyroxine, or makes weight loss easier.

Those claims are not equally supported, and several have not been demonstrated in clinical trials.

Direct answer: LDN is sometimes prescribed off label for selected symptoms in people who have Hashimoto’s disease, but current evidence does not establish that it treats Hashimoto’s thyroiditis, lowers thyroid antibodies, restores thyroid function, reduces thyroid-hormone requirements, or promotes weight loss. LDN should not replace prescribed levothyroxine or endocrinology follow-up.

The most directly relevant published study followed thyroid-hormone dispensing in 898 people with hypothyroidism before and after they started LDN. Researchers found no association between LDN initiation and reduced use of levothyroxine or triiodothyronine. If anything, levothyroxine use tended to increase with greater LDN exposure. The study was observational and did not measure symptoms, antibody levels, or laboratory thyroid function, but its findings do not support claims that LDN reduces the need for thyroid hormone. Read the open-access study.

If you are new to the medicine, begin with Scripx Pharmacy’s guide to what Low Dose Naltrexone is, including its uses, evidence, safety, and compounding. You can also compare the condition-specific research in LDN for autoimmune conditions: what has actually been studied.

Considering LDN or Weight-Management Treatment With Hashimoto’s?

Do not change levothyroxine, liothyronine, desiccated thyroid, LDN, or a weight-management medication on your own. Ask the prescribing clinician to define the goal of each therapy, review current thyroid laboratory results, reconcile every medication and supplement, and establish a follow-up plan.

If a licensed prescriber believes an individualized LDN prescription may be appropriate for a separate symptom goal, review Scripx Pharmacy’s Low Dose Naltrexone compounding services and contact a Scripx compounding pharmacistwith questions about the prescription, formulation, inactive ingredients, timing, opioid safety, and medication coordination. For obesity or another appropriate metabolic indication, explore Scripx Pharmacy’s medically supervised weight-management services.

All medications require a valid prescription from a licensed healthcare provider. The LDN uses discussed here are off label, compounded medications are not FDA approved, and weight-management treatment must be evaluated separately from Hashimoto’s treatment.

Hashimoto’s Thyroiditis and Hypothyroidism Are Related, but Not Identical

Hashimoto’s thyroiditis is an autoimmune condition in which the immune system targets the thyroid. Over time, this can damage the gland and reduce its ability to produce thyroid hormone. That resulting hormone deficiency is called hypothyroidism.

A person can have thyroid antibodies associated with Hashimoto’s while thyroid-stimulating hormone, or TSH, and free T4 remain normal. The American Thyroid Association explains that people with elevated thyroid antibodies but normal thyroid-function tests generally do not require thyroid-hormone treatment. They do require appropriate monitoring because hypothyroidism can develop later.

When clinical hypothyroidism is present, the established treatment is thyroid-hormone replacement, most commonly levothyroxine. The dose is adjusted using TSH and the patient’s clinical circumstances. Most people with hypothyroidism caused by Hashimoto’s require long-term or lifelong replacement therapy.

This creates three separate questions that should not be collapsed into one:

1. Is autoimmune thyroiditis present?

2. Is the thyroid producing enough hormone?

3. What is causing a particular symptom, such as fatigue, brain fog, constipation, pain, or weight change?

LDN discussions often blur those questions. A change in one symptom would not prove that thyroid antibodies fell, thyroid tissue recovered, or thyroid-hormone replacement was no longer needed.

Why Is LDN Discussed for Hashimoto’s Disease?

Naltrexone is an opioid receptor antagonist approved at standard doses for alcohol dependence and blockade of externally administered opioids. “Low Dose Naltrexone” describes lower-dose, off-label use. There is no single FDA-defined LDN dose and no FDA-approved LDN indication for Hashimoto’s disease, hypothyroidism, fatigue, inflammation, or weight loss.

The interest in Hashimoto’s largely comes from proposed immune and inflammatory mechanisms, limited studies of LDN in other conditions, clinician experience, and patient reports. These sources can generate research questions, but they cannot substitute for condition-specific trials.

Mechanistic plausibility is especially easy to overstate. A medication can affect a laboratory pathway or immune signal without producing a meaningful clinical outcome. For Hashimoto’s, useful trials would need to evaluate endpoints such as:

• Patient-reported symptoms using validated measures

• TSH and free T4

• Thyroid-peroxidase or thyroglobulin antibody trends, interpreted carefully

• Levothyroxine requirements

• Thyroid size or structural outcomes when clinically relevant

• Quality of life

• Adverse effects and opioid-related safety

• Durability of any benefit

Those data are not currently available from large, well-controlled Hashimoto’s trials.

What Has Actually Been Studied?

The 898-Patient Norwegian Prescription Study

The most relevant published human evidence is a 2020 quasi-experimental study using the Norwegian Prescription Database. Investigators identified 898 people with hypothyroidism who started LDN and compared the amount of levothyroxine and triiodothyronine dispensed during the year before and the year after LDN initiation.

Starting LDN was not associated with a subsequent reduction in thyroid-hormone dispensing. Greater LDN exposure also did not produce evidence of a dose-response reduction in thyroid medication. The authors concluded that the results did not support efficacy claims for LDN in hypothyroidism.

This study has important limitations:

1. It measured prescriptions dispensed, not whether the medication was taken.

2. It did not include TSH, free T4, antibody levels, weight, or symptom scores.

3. It could not separate Hashimoto’s disease from every other cause of hypothyroidism.

4. It was not a randomized trial.

5. It could not determine whether a subset of patients experienced symptom benefit unrelated to thyroid-hormone use.

The study therefore does not prove that LDN never helps any symptom in a person with Hashimoto’s. It does show why the specific claim that LDN reduces thyroid-hormone requirements should not be presented as established.

The 2026 Review of 105 LDN Studies

A 2026 narrative review evaluated 105 LDN studies across chronic pain, autoimmune and neuroimmune disorders, gastrointestinal disease, dermatology, post-infectious syndromes, mental health, and oncology. Only 15 were randomized controlled trials. The authors reported that early positive findings from uncontrolled studies were rarely replicated in placebo-controlled research and concluded that current evidence does not support routine clinical use. Read the 2026 evidence review.

The review did not establish Hashimoto’s disease as a condition with supportive randomized evidence. Its broader lesson is directly relevant: evidence from another autoimmune condition cannot be assumed to apply to autoimmune thyroid disease.

Reviews of Alternative Thyroid Approaches

A peer-reviewed review of diet and alternative approaches to thyroid disease concluded that LDN has little to no evidence of impact on thyroid disease. This does not make every patient report meaningless. It means testimonials, mechanistic explanations, and experience-based protocols should not be described as proof of reduced autoimmunity or restored thyroid function. Read the PubMed review.

LDN and Hashimoto’s: Evidence at a Glance

Question	What the evidence shows	What has not been established
Does LDN treat Hashimoto’s thyroiditis?	No condition-specific randomized trial establishes efficacy	Control, remission, or reversal of Hashimoto’s disease
Does LDN lower TPO or thyroglobulin antibodies?	No reliable controlled evidence establishes a reduction	A predictable or clinically meaningful antibody response
Does LDN restore thyroid function?	Not demonstrated	Recovery of thyroid-hormone production or thyroid tissue
Does LDN reduce levothyroxine needs?	A study of 898 people found no reduction in thyroid-hormone dispensing	Ability to replace or routinely reduce thyroid hormone
Does LDN improve fatigue, pain, or brain fog?	Hashimoto’s-specific evidence is inadequate	Consistent symptom benefit attributable to LDN
Does LDN cause weight loss?	LDN alone is not an established obesity treatment	Reliable weight reduction or enhancement of GLP-1 therapy
Can LDN replace thyroid follow-up?	No	Replacement of TSH monitoring, clinical review, or endocrinology care

The most accurate conclusion is not that every LDN experience will be negative. It is that Hashimoto’s-specific efficacy remains unproven, and LDN should not be used as evidence that thyroid disease is controlled.

LDN Is Not a Replacement for Levothyroxine

Levothyroxine replaces hormone that an underactive thyroid can no longer produce adequately. LDN does not supply thyroid hormone. Even if a patient reports improvement in pain, sleep, mood, or energy after beginning LDN, that change does not demonstrate normal thyroid-hormone production.

The American Thyroid Association’s Hashimoto’s guidance recommends levothyroxine for clinical hypothyroidism and dose adjustment based on TSH. Stopping or reducing replacement therapy without laboratory and clinical review can allow hypothyroidism to recur or worsen. Increasing thyroid medication without guidance can also cause symptoms and risks associated with excessive thyroid hormone.

Patients should not respond to a new symptom by changing both LDN and thyroid medication at the same time. Doing so makes it difficult to determine whether the symptom came from thyroid status, LDN, another medication, weight change, illness, sleep, nutrition, menopause, anemia, mood, or another factor.

For a broader medication review, read LDN drug interactions involving opioids, GLP-1s, antidepressants, thyroid medications, and more.

What if Symptoms Persist Even When TSH Is in Range?

Persistent symptoms deserve attention, but they do not automatically prove ongoing thyroid autoimmunity, poor medication absorption, or a need for LDN.

Fatigue, weight change, poor sleep, depressed mood, cognitive complaints, constipation, hair changes, muscle discomfort, and reduced exercise tolerance are real but nonspecific. They can occur with thyroid dysfunction and with many other conditions. A structured review may include:

1. Confirmation of the diagnosis and recent TSH and free T4 results

2. How thyroid medication is taken, including timing, consistency, food, supplements, and other drugs

3. Changes in weight, pregnancy status, estrogen exposure, gastrointestinal disease, or other factors that can affect thyroid-hormone needs

4. Sleep quality and possible sleep apnea

5. Iron, vitamin B12, or other deficiencies when clinically indicated

6. Depression, anxiety, chronic pain, menopause, or another contributor

7. Medication adverse effects or interactions

8. A specific, measurable goal if an off-label adjunct is considered

This approach validates the symptom without turning a single theory into a diagnosis.

Hashimoto’s, Weight Gain, and the GLP-1 Crossover

Weight concerns are one of the most important reasons people with Hashimoto’s search for LDN, GLP-1 medications, and newer agents such as retatrutide.

Hypothyroidism can contribute to weight gain, fluid retention, fatigue, and lower activity. Correcting a true thyroid-hormone deficiency remains important. However, returning TSH to the target range does not produce major weight loss for every patient. The American Thyroid Association has reported that weight loss after successful levothyroxine treatment is often modest and does not occur in everyone. Read the ATA summary.

That is why weight management and thyroid replacement should be treated as connected but distinct plans.

• Thyroid treatment addresses hormone deficiency.

• Obesity treatment addresses a chronic metabolic disease using its own eligibility criteria, benefits, risks, and monitoring.

• LDN remains an off-label medication without established efficacy for Hashimoto’s or weight loss.

A person can have well-treated hypothyroidism and still meet criteria for obesity treatment. A person can also have abnormal thyroid function that should be addressed before unexplained symptoms are attributed solely to weight.

Can Someone With Hashimoto’s Use a GLP-1 Medication?

Hashimoto’s thyroiditis by itself is not listed as an FDA contraindication to Wegovy, Zepbound, or other incretin-based medicines. That does not mean these drugs are appropriate for every person with Hashimoto’s.

FDA-approved obesity medications such as semaglutide and tirzepatide have defined indications, warnings, contraindications, adverse effects, and monitoring considerations. The prescribing clinician should review thyroid-cancer history, gastrointestinal symptoms, pregnancy plans, pancreatitis and gallbladder history, kidney risk related to dehydration, diabetes medications, and the complete medication list.

The thyroid boxed warning is frequently misunderstood. Current labeling for Wegovy and Zepbound warns about thyroid C-cell tumors observed in rodents and states that it is unknown whether these medicines cause medullary thyroid carcinoma, or MTC, in humans. They are contraindicated in people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2, known as MEN 2. Review the current Wegovy labeling and current Zepbound labeling.

Hashimoto’s is an autoimmune thyroid condition. MTC arises from thyroid C cells and is a different disease. Patients should not assume that every “thyroid condition” creates the same risk, nor should they dismiss the boxed warning without an individualized history review.

Why Thyroid-Medication Monitoring Matters With GLP-1 Therapy

Medication coordination matters for at least three reasons.

1. Delayed Gastric Emptying

Semaglutide and tirzepatide can delay gastric emptying and may affect the absorption of oral medications. Zepbound labeling advises caution with oral medicines and monitoring for drugs that depend on threshold concentrations. This does not prove that every patient’s levothyroxine absorption will change, but it supports a plan for clinical and laboratory follow-up.

2. Direct Oral Semaglutide Interaction Data

The 2026 labeling for oral semaglutide reports that levothyroxine exposure increased by 33% when the two were administered together in a drug-interaction study. The label recommends increased clinical or laboratory monitoring when oral semaglutide is used with oral drugs requiring monitoring. Review the FDA labeling.

That specific finding should not be automatically extrapolated to every injectable GLP-1 medicine. It does demonstrate why the exact product, dosage form, administration timing, and thyroid-monitoring plan matter.

3. Meaningful Weight Change

Substantial weight change can alter medication requirements in some patients. The answer is not to preemptively change levothyroxine. It is to monitor TSH and symptoms according to the treating clinician’s plan and adjust only when supported by the full clinical picture.

Where Does Retatrutide Fit in 2026?

Retatrutide is a once-weekly investigational triple agonist that activates GIP, GLP-1, and glucagon receptors. Lilly has reported positive topline results from multiple Phase 3 trials, including studies in obesity and type 2 diabetes. The emerging results are important, but topline announcements are not the same as FDA approval, complete peer-reviewed data, or an individualized prescribing decision.

As of August 2026:

1. Retatrutide is not FDA approved.

2. It is not available for routine public prescribing.

3. Lilly states that it is legally available only through its clinical trials.

4. FDA states that retatrutide cannot be used in compounding under federal law.

5. Products sold online as “research” or “compounded” retatrutide should not be treated as legitimate alternatives to approved medication.

Lilly’s July 2026 medical update describes retatrutide as investigational and not available for public use. Read Lilly’s retatrutide status page. FDA states that retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in compounding under federal law. Read the FDA safety notice.

There is no established retatrutide treatment protocol for Hashimoto’s disease, no approved retatrutide and LDN combination, and no evidence that retatrutide treats autoimmune thyroiditis.

Should LDN Be Combined With a GLP-1 or Retatrutide?

There is not adequate evidence to promote LDN plus semaglutide, tirzepatide, or another incretin therapy as a superior weight-loss protocol. LDN is also not the same as Contrave, the FDA-approved fixed-dose combination of naltrexone and bupropion used for chronic weight management in appropriate patients.

If LDN and an approved GLP-1 or GIP/GLP-1 medication are considered for different clinical reasons, the care team should clarify:

1. The indication and goal for each medication

2. Whether LDN has a specific symptom target

3. Baseline thyroid function and the thyroid-hormone regimen

4. Gastrointestinal symptoms and oral medication timing

5. Nausea, constipation, sleep, mood, and other potentially overlapping effects

6. Current or anticipated opioid exposure

7. Surgery, dental work, or emergency-pain planning

8. How weight, symptoms, TSH, and adverse effects will be monitored

Retatrutide should not be included in such a routine plan because it is investigational and not legally available outside clinical trials.

The Opioid Warning Still Comes First With LDN

LDN contains naltrexone, an opioid receptor antagonist. A lower dose does not eliminate the possibility of blocking opioid analgesia or precipitating withdrawal in a person who is physiologically dependent on opioids.

This matters before surgery, dental treatment, an injury, emergency care, or treatment of acute pain. Patients should not stop an opioid, create their own opioid-free interval, stop LDN before a procedure, or attempt to overcome opioid blockade without direct guidance.

Review the Scripx guide to LDN side effects and opioid safety and make sure every clinician involved in a planned procedure knows about LDN.

Eight Questions to Ask the Prescriber, Endocrinologist, and Pharmacist

1. Is my current symptom likely to reflect thyroid dysfunction, or should other causes be evaluated?

2. What are my recent TSH and free T4 results, and what is the monitoring goal?

3. What specific outcome would LDN be intended to address?

4. What Hashimoto’s-specific evidence supports that goal?

5. How will we avoid interpreting symptom change as proof that autoimmune thyroid disease improved?

6. If a GLP-1 or GIP/GLP-1 medicine is prescribed for obesity, how will oral thyroid medication and TSH be monitored?

7. Do I have any current, recent, or anticipated opioid exposure?

8. Which change should be made first so that benefits and adverse effects can be attributed more clearly?

Patients evaluating a compounded LDN prescription can also review 10 questions to ask an LDN compounding pharmacy.

The Bottom Line

LDN is discussed frequently for Hashimoto’s disease, but online enthusiasm exceeds the condition-specific evidence. There are no convincing randomized trials showing that LDN lowers thyroid antibodies, restores thyroid function, reduces thyroid-hormone requirements, treats Hashimoto’s symptoms, or produces weight loss.

The most relevant published study included 898 people with hypothyroidism and found no reduction in thyroid-hormone dispensing after LDN initiation. A 2026 review of 105 LDN studies also concluded that evidence across conditions does not currently support routine clinical use.

GLP-1 and GIP/GLP-1 medications belong in a separate metabolic-care discussion. They may be appropriate for an FDA-approved obesity or diabetes indication after individual evaluation. Hashimoto’s itself is not the same as the MTC or MEN 2 contraindications in current labeling, but thyroid history, oral medication absorption, levothyroxine monitoring, and meaningful weight change still require coordination.

Retatrutide is an important investigational therapy with positive Phase 3 topline results. It is not FDA approved, not available for routine prescribing, and cannot legally be compounded. It should not be marketed as a current Hashimoto’s or weight-management option.

Take the Next Step With Scripx Pharmacy

If a licensed prescriber believes compounded LDN may be appropriate for a defined, individualized symptom goal, learn about Scripx Pharmacy’s LDN compounding services and contact a Scripx compounding pharmacist to review the prescription, dosage form, inactive ingredients, medication timing, and opioid safety.

If your primary concern is obesity or metabolic health, explore Scripx Pharmacy’s medically supervised weight-management services. Weight-management therapy should be evaluated on its own indication and should not replace thyroid-hormone treatment or endocrinology follow-up.

Do not reduce or stop thyroid hormone based on a symptom change, antibody claim, or online LDN protocol. Do not purchase a product sold as retatrutide. Coordinate thyroid, weight-management, and LDN decisions with the licensed clinicians and pharmacists responsible for your care.

All prescriptions require review and approval by a licensed healthcare provider. LDN uses discussed here are off label. Compounded medications are not FDA approved, and individual results vary.

Frequently Asked Questions

Does LDN treat Hashimoto’s disease?

Current evidence does not establish LDN as a treatment for Hashimoto’s thyroiditis. It may be prescribed off label for a selected symptom goal, but that is different from proving that it controls autoimmune thyroid disease.

Can LDN lower thyroid antibodies?

Reliable controlled clinical evidence has not established that LDN predictably lowers thyroid-peroxidase or thyroglobulin antibodies. Antibody changes should not be promised or used alone to determine whether a therapy is effective.

Can LDN replace levothyroxine?

No. LDN does not replace missing thyroid hormone. In a study of 898 people with hypothyroidism, starting LDN was not associated with reduced dispensing of levothyroxine or triiodothyronine.

Does LDN help fatigue or brain fog from Hashimoto’s?

Hashimoto’s-specific evidence is inadequate to establish consistent improvement. Fatigue and brain fog are nonspecific and may reflect thyroid status, sleep, mood, pain, anemia, menopause, another medication, or another condition.

Does LDN cause weight loss?

LDN alone is not an FDA-approved or established obesity treatment. It should not be confused with Contrave, which is a fixed-dose combination of naltrexone and bupropion with its own approval, dosing, contraindications, and safety profile.

Can a person with Hashimoto’s take semaglutide or tirzepatide?

Possibly, when there is an appropriate approved indication and the prescriber determines that benefits and risks are acceptable. Hashimoto’s itself is not listed as an FDA contraindication, but the complete thyroid history, MTC or MEN 2 history, medications, gastrointestinal health, pregnancy plans, and monitoring needs must be reviewed.

Do GLP-1 medicines carry a thyroid warning?

Yes. Current Wegovy and Zepbound labels contain boxed warnings about thyroid C-cell tumors observed in rodents and contraindicate use in people with a personal or family history of medullary thyroid carcinoma or MEN 2. It is unknown whether these medicines cause MTC in humans.

Can GLP-1 therapy affect levothyroxine?

GLP-1 and GIP/GLP-1 therapies can delay gastric emptying and may affect oral medication absorption. Oral semaglutide labeling reports increased levothyroxine exposure in a drug-interaction study. The exact product and thyroid-monitoring plan should be reviewed with the prescriber and pharmacist.

Is retatrutide available for Hashimoto’s or weight loss?

No. As of August 2026, retatrutide is investigational, not FDA approved, and not available for routine public prescribing. FDA states that it cannot be used in compounding under federal law.

Can LDN be combined with a GLP-1 medication?

There is no established LDN-plus-GLP-1 weight-loss protocol. If the medicines are prescribed for separate reasons, the care team should review oral medication absorption, gastrointestinal effects, thyroid monitoring, opioids, and a clear outcome plan for each therapy.